Prolacta Bioscience Market Research Report
Background
Company Overview
Prolacta Bioscience, established in 1999, is a privately held life sciences company headquartered in Duarte, California. The company is dedicated to advancing the science of human milk to improve the health of critically ill and premature infants. Prolacta is the world's leading provider of 100% human milk-based nutritional products, having touched the lives of more than 125,000 premature infants globally.
Mission and Vision
Prolacta's mission is to discover, develop, and deliver life-changing solutions for critically ill babies and other vulnerable patients through innovative human milk research and leadership in quality and safety. The company's vision is to give babies a brighter future by unlocking the biological power of human milk.
Industry Significance
Prolacta has been instrumental in changing the standard of care for extremely premature infants worldwide by introducing the first nutritional fortifiers made from 100% donor human milk instead of cow milk. These fortifiers have been clinically proven to reduce complications and improve health outcomes for vulnerable infants.
Key Strategic Focus
Core Objectives
Prolacta aims to advance neonatal nutrition by providing human milk-based nutritional products that improve health outcomes for critically ill and premature infants. The company is also exploring the therapeutic potential of human milk across a wide spectrum of diseases, including applications for infants requiring surgery for congenital cardiac and gastrointestinal disorders.
Areas of Specialization
Prolacta specializes in the development and provision of human milk-based nutritional products, including fortifiers and formulas, for neonatal intensive care units (NICUs). The company also focuses on research into the therapeutic applications of human milk.
Key Technologies Utilized
Prolacta operates the world's first pharmaceutical-grade human milk processing facilities, employing vat pasteurization and a patented, FDA-reviewed manufacturing process to ensure pathogen inactivation while protecting the nutritional composition and bioactivity of its human milk-based products.
Primary Markets Targeted
Prolacta's primary markets include neonatal intensive care units (NICUs) in hospitals worldwide, with a focus on extremely premature infants weighing less than 1,250 grams (2.75 pounds). The company has expanded its reach to over 10 countries, including recent approvals in Australia and ongoing efforts in Europe and Japan.
Financials and Funding
Funding History
Prolacta has raised significant capital through various funding rounds to support its growth and expansion. Notable funding events include:
- December 2016: Raised $35 million in a mezzanine financing round led by Essex Woodlands, with participation from Aisling Capital and existing shareholder Health Evolution Partners.
- November 2011: Secured Series D funding from Health Evolution Partners to support the expansion of its commercial presence and sales organization.
Total Funds Raised
As of the latest available data, Prolacta has raised a total of at least $81.7 million across multiple funding rounds.
Notable Investors
Key investors in Prolacta include Essex Woodlands, Aisling Capital, and Health Evolution Partners.
Utilization of Capital
Proceeds from these funding rounds have been utilized to expand Prolacta's commercial presence, particularly in European markets, support clinical trials for its human milk-based nutritional products, and advance the company's therapeutic development plans, including the evaluation of human milk oligosaccharides (HMOs) for treating various microbiome-related diseases.
Pipeline Development
Key Pipeline Candidates
Prolacta's pipeline includes:
- Surgifort®: The first and only FDA-approved human milk-based fortifier designed for term infants recovering from corrective surgery for gastroschisis.
Stages of Development
Surgifort® has received FDA approval and is available for use in the United States.
Target Conditions
Surgifort® is specifically designed for term infants recovering from corrective surgery for gastroschisis.
Anticipated Milestones
Prolacta continues to monitor the clinical outcomes associated with Surgifort® and plans to expand its use based on ongoing research and feedback from healthcare providers.
Technological Platform and Innovation
Proprietary Technologies
Prolacta's proprietary technologies include its vat pasteurization process and FDA-reviewed manufacturing techniques, which ensure pathogen inactivation while preserving the nutritional composition and bioactivity of human milk-based products.
Significant Scientific Methods
The company employs rigorous screening and testing protocols, including over 20 validated tests for screening and testing human milk, to maintain the highest quality and safety standards.
Leadership Team
Key Executives
- Scott Elster: Chief Executive Officer. Elster has been with Prolacta since 2007, leading the company through significant growth and product development milestones.
- Dr. Melinda Elliott: Chief Medical Officer. Dr. Elliott has extensive experience in neonatology and has been instrumental in advancing Prolacta's clinical research initiatives.
- Alan Kofsky: Vice President, Sales North America & Europe and Global Marketing. Kofsky oversees Prolacta's sales and marketing strategies across multiple regions.
Leadership Changes
As of the latest available information, there have been no recent significant changes or appointments within Prolacta's leadership team.
Competitor Profile
Market Insights and Dynamics
The market for human milk-based nutritional products is growing, driven by increasing awareness of the benefits of human milk for premature and critically ill infants. Prolacta faces competition from both established companies and emerging startups in the neonatal nutrition space.
Competitor Analysis
Key competitors include:
- Enfamil: A leading brand in infant nutrition, offering a range of products including formulas and fortifiers.
- Similac: Another major player in the infant nutrition market, providing various formula products.
- Medolac Laboratories: A company specializing in shelf-stable, human milk-based infant nutrition products.
Strategic Collaborations and Partnerships
Prolacta has established partnerships with various organizations to enhance its product offerings and expand its reach. For example, the company has collaborated with the National Black Nurses Association to support initiatives aimed at improving neonatal nutrition.
Operational Insights
Prolacta's commitment to quality and safety, along with its focus on human milk-based products, differentiates it from competitors. The company's proprietary manufacturing processes and rigorous testing protocols set high industry standards.
Strategic Opportunities and Future Directions
Strategic Roadmap
Prolacta plans to continue expanding its product portfolio, focusing on human milk-based nutritional products for both premature and term infants. The company aims to leverage its expertise in human milk science to explore new therapeutic applications.
Future Business Directions
Prolacta is exploring opportunities to enter new international markets, including ongoing efforts in Europe and Japan. The company is also considering business development opportunities to further its mission of advancing neonatal nutrition.
Opportunities for Expansion
The growing recognition of the benefits of human milk-based nutrition presents opportunities for Prolacta to expand its market share. Strategic partnerships and collaborations can further enhance the company's reach and impact.
Contact Information
Prolacta Bioscience's official website is www.prolacta.com. The company maintains an active presence on social media platforms, including Twitter, Instagram, Facebook, and LinkedIn.
